Neuroimmunology Unit, Department of Neurosciences, Hospital Alemán, Buenos Aires.
Neuroimmunology Unit, Department of Neurosciences, Hospital Alemán, Buenos Aires.
Mult Scler Relat Disord. 2021 Apr;49:102742. doi: 10.1016/j.msard.2021.102742. Epub 2021 Jan 7.
Myelin oligodendrocyte glycoprotein antibodies (MOG-ab) have been described in aquaporin-4-antibodies(AQP4-ab)-negative neuromyelitis optica spectrum disorder (NMOSD) patients. We aimed to evaluate the percentage of AQP4-ab-negative NMOSD patients who are positive for MOG-ab in a cohort of Argentinean patients included in RelevarEM (Clinical Trials registry number NCT03375177).
RelevarEM is a longitudinal, strictly observational multiple sclerosis (MS) and NMOSD registry in Argentina. Of 3031 consecutive patients (until March 2020), 165 patients with phenotype of suspected NMOSD, whose relevant data for the purpose of this study were available, were included. Data on demographic, clinical, paraclinical and treatment in AQP4-ab (positive, negative and unknown) and MOG-ab (positive and negative) patients were evaluated.
A total of 165 patients (79 AQP4-Ab positive, 67 AQP4-Ab negative and 19 unknown) were included. Of these, 155 patients fulfilled the 2015 NMOSD diagnostic criteria. Of 67 AQP4-Ab-negative patients, 36 (53.7%) were tested for MOG-Ab and 10 of them (27.7%) tested positive. Serum AQP4-ab levels were tested by means of cell-based assay (CBA) in 48 (35.2%), based on tissue-based indirect immunofluorescence assays in 58 (42.6%) and enzyme-linked immunosorbent assay in 4 (2.9%). All MOG-ab were tested by CBA. Optic neuritis (90%) was the most frequent symptom at presentation and optic nerve lesions the most frequent finding (80%) in neuroimaging of MOG-ab-associated disease. Of these, six (60%) patients were under immunosuppressant treatments at latest follow-up.
We observed that 27.7% (10/36) of the AQP4-ab-negative patients tested for MOG-ab were positive for this antibody, in line with results from other world regions.
髓鞘少突胶质细胞糖蛋白抗体（MOG-ab）已在水通道蛋白 4 抗体（AQP4-ab）阴性视神经脊髓炎谱系疾病（NMOSD）患者中描述。我们旨在评估在 RelevarEM（临床试验注册号 NCT03375177）中纳入的一组阿根廷患者中，AQP4-ab 阴性 NMOSD 患者中 MOG-ab 阳性的比例。
RelevarEM 是阿根廷一项纵向、严格观察性的多发性硬化症（MS）和 NMOSD 登记处。在 3031 例连续患者（截至 2020 年 3 月）中，纳入了 165 例具有疑似 NMOSD 表型的患者，这些患者的相关数据可用于本研究。评估了 AQP4-ab（阳性、阴性和未知）和 MOG-ab（阳性和阴性）患者的人口统计学、临床、实验室和治疗数据。
共纳入 165 例患者（79 例 AQP4-Ab 阳性、67 例 AQP4-Ab 阴性和 19 例未知）。其中 155 例符合 2015 年 NMOSD 诊断标准。在 67 例 AQP4-Ab 阴性患者中，36 例（53.7%）接受了 MOG-Ab 检测，其中 10 例（27.7%）检测结果阳性。血清 AQP4-ab 水平通过基于细胞的测定法（CBA）在 48 例（35.2%）、基于组织间接免疫荧光测定法在 58 例（42.6%）和酶联免疫吸附测定法在 4 例（2.9%）中进行了检测。所有 MOG-ab 均通过 CBA 进行了检测。视神经炎（90%）是最常见的首发症状，视神经病变是 MOG-ab 相关疾病神经影像学中最常见的发现（80%）。其中，6 例（60%）患者在最近的随访中接受了免疫抑制剂治疗。
我们观察到，在接受 MOG-ab 检测的 36 例 AQP4-ab 阴性患者中，有 27.7%（10/36）为该抗体阳性，与其他世界区域的结果一致。
